01 / DESIGN
What was studied?
This randomized trial enrolled 17,604 adults aged at least 45 with established cardiovascular disease and overweight or obesity, but no history of diabetes.
02 / FINDINGS
What did the researchers report?
The composite cardiovascular endpoint occurred in 6.5% of the semaglutide group and 8.0% of the placebo group during follow-up. Adverse events leading to permanent treatment discontinuation were more frequent with semaglutide.
03 / LIMITS
How should it be interpreted?
These findings concern secondary prevention in an already high-risk population. They should not be generalized to healthy people, all cardiovascular conditions or untested research materials.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.